Balchem Corporation (BCPC)
NEUTRALFundamental
71
Price
$177.16
Market Cap
$5.79B
Part 1 · What the company is worth
Overview
Balchem Corporation develops, manufactures, and distributes specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment offers specialty vitamin K2; microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; methylsulfonylmethane; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment distributes ethylene oxide and ammonia primarily for use in the health care industry; and single use canisters for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. It sells its products through sales force, independent distributors, and sales agents. The company was incorporated in 1967 and is headquartered in Montvale, New Jersey.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance Sheet & Liquidity
Revenue
$1.09B
Trailing 12 months (through 6/30/2026)
Net Income
$164M
Trailing 12 months (through 6/30/2026)
Free Cash Flow
-
Total Equity
$1.26B
Total Liabilities
$429M
Current Ratio
2.66
Interest Coverage
-
Debt/EBITDA
0.65
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$126.59
Current Price
$177.16
Margin of Safety
-40.0%
Fair Value Range
$82.29 - $170.90
Estimation Methods
Valuation Metrics
P/E Ratio
34.87
ROE
12.3%
P/B Ratio
4.34
P/FCF
-
Gross Margin
36.3%
ROIC
10.9%
Profitability Radar
Value Creation (Economic Moat)
ROIC
10.9%
WACC
9.0%
ROIC − WACC
+2.0 pp
ROIC exceeds the cost of capital — the company is creating value for shareholders.
Fundamental Analysis Criteria
Passed (17)
- EPS shows upward trend
- EPS CAGR 10.73%
- Price CAGR 8.01%
- ROIC 11.0%
- Gross Margin 36.3%
- Debt/Equity ratio
- Operating Margin 20.2%
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- ROE 12.8%
- Revenue Growth 5Y 8.1%
- Analyst Consensus 78% Buy
- Earnings Quality (OCF/NI) 1.34
- Share Dilution -0.3%
- Net Margin Trend 15.1% vs 14.5%
- Piotroski F-Score 9/9
Failed (6)
- P/B Ratio 4.34
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Earnings Surprise avg 0.9%
- PEG Ratio 2.72
Unavailable (5)
- P/FCF NaN
- Dividend Payout NaN%
- Positive Free Cash Flow
- CapEx intensity
- Interest Coverage
Piotroski F-Score
Strong financial health
Earnings Quality
High quality: earnings backed by cash
Share Dilution
Buying back shares. Shareholder friendly
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Mr. Theodore Lee Harris | CEO, President & Chairman | 60 |
| Mr. Carl Martin Bengtsson | Executive VP, CFO, Treasurer and GM of Animal Nutrition & Health | 48 |
| Ms. Hatsuki Miyata J.D. | Executive VP, Chief Legal Officer & Secretary | 49 |
| Mr. M. Brent Tignor | Senior VP & Chief Human Resources Officer | 47 |
| Mr. Frederic Boned | Senior VP, Head of Digital Transformation & AI and GM of Human Nutrition & Health | 46 |
| Ms. Erin L. Gilson | VP & Chief Accounting Officer | - |
| Mr. Martin Luther Reid | Senior VP & Chief Supply Chain Officer | 58 |
| Mr. Job L. van Gunsteren | Senior VP & GM of Specialty Products | 48 |
| Mr. George Graham | Senior VP and Chief R&D Officer | 55 |
Audit Risk
3
Board Risk
4
Compensation Risk
4
Shareholder Rights Risk
7
Part 2 · The price and when to enter
This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Latest News
Recent headlines for BCPC, sourced from Markets Gazette.